%PDF-1.4
%
25 0 obj
<>
endobj
22 0 obj
<>
endobj
78 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-03-05T15:16:22Z
2024-03-29T08:11:46-07:00
QuarkXPressª 4.11: AdobePS 8.6 (219)
2024-03-29T08:11:46-07:00
application/pdf
Heather
2002-1096.omeract.april
uuid:4832aab9-1dd2-11b2-0a00-8f08275dc400
uuid:4832aabb-1dd2-11b2-0a00-810000000000
endstream
endobj
11 0 obj
<>
endobj
12 0 obj
<>
endobj
26 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
92 0 obj
[96 0 R]
endobj
93 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/T1_0 1 Tf
0.0163 Tc 0.3586 Tw 10 0 0 10 54 713.1616 Tm
(knowledge on patient-based outcomes \(that pain and)Tj
-0.00011 Tc 0.0041 Tw 0 -1.2 TD
(mobility are very important\) but raise some new and impor-)Tj
0.02499 Tw T*
(tant issues:)Tj
0.3414 Tw T*
(\245 Some outcomes of importance to patients may not)Tj
0.02499 Tw T*
[(currently be measured in assessments of treatment ef)17.7 (ficacy)]TJ
0.23531 Tw T*
(\245 For some of these outcomes, there may be validated)Tj
0.3427 Tw T*
(outcome measures available, but for others our under-)Tj
-0.01601 Tw T*
(standing of the meaning of the outcome and how to quantify)Tj
0.14349 Tw T*
(it are either absent or are very rudimentary \(for example,)Tj
-0.037 Tw T*
(assessment of wellness or well-being, or return to normality\))Tj
0.01221 Tw T*
[(\245 )17.7 (The challenge for outcome assessment is how to calibrate)]TJ
0.0352 Tw T*
(new and existing measures to take account of \(a\) variations)Tj
0.2325 Tw T*
[(in the weighting of importance of dif)17.7 (ferent outcomes at)]TJ
0.19341 Tw T*
[(dif)17.7 (ferent stages of disease and in dif)17.7 (ferent circumstances)]TJ
0.11189 Tw T*
(\(e.g., when pain is more important than mobility and vice)Tj
0.035 Tw T*
(versa\) and \(b\) variations in the magnitude of change within)Tj
0.0777 Tw T*
(the same outcome that is considered evidence of treatment)Tj
0.13091 Tw T*
[(ef)17.7 (ficacy at dif)17.7 (ferent stages of disease \(e.g., small vs lar)17.7 (ge)]TJ
0.16479 Tw T*
(changes in pain, depending on whether it is early or late)Tj
0 Tw T*
(disease\).)Tj
/T1_1 1 Tf
0 -2.4 TD
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 451.1616 Tm
[(1.)-875.1 (Fries JF)79.7 (, Spitz P)110.7 (, Kraines RG, Holman HR. Measurement of patient)]TJ
1.675 -1.25 Td
[(outcome in arthritis. )54.8 (Arthritis Rheum 1980;23:137-45.)]TJ
-1.675 -1.25 Td
[(2.)-875.1 (Meenan RF)79.7 (, Gertman PM, Mason JM. Measuring health status in)]TJ
1.675 -1.25 Td
[(arthritis: the )54.8 (Arthritis Impact Measurement Scale. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw 0 -1.25 TD
(1980;23:146-52.)Tj
-0.00011 Tc 0.02499 Tw 31.325 37.921 Td
[(3.)-875.1 (Euroqol Group. Euroqol EQ-5D User Guide. Rotterdam: Rotterdam)]TJ
1.675 -1.25 Td
[(Centre for Health Policy and Law)64.8 (, Erasmus University; 1996.)]TJ
-1.675 -1.25 Td
[(4.)-875.1 (W)79.9 (are JE, Sherbourne CD. )17.7 (The MOS 36-item Short-form Health)]TJ
1.675 -1.25 Td
(Survey \(SF-36\) I. Conceptual framework and item selection. Med)Tj
T*
(Care 1992;30:473-83.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (O\325Boyle CA, McGee H, Hickey )54.8 (A, O\325Malley K, Joyce CRB.)]TJ
1.675 -1.25 Td
[(Individual quality of life in patients under)17.7 (going hip replacement.)]TJ
T*
(Lancet 1992;339:1088-91.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (De Jong Z, van der Heijde D, McKenna SP)110.7 (, )17.7 (Whalley D. )17.7 (The )]TJ
1.675 -1.25 Td
(reliability and construct validity of the RAQoL: a rheumatoid)Tj
T*
(arthritis-specific quality of life instrument. Br J Rheumatol)Tj
0 Tc 0 Tw T*
(1997;36:878-83.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(7.)-875.1 (Carr )54.8 (AJ, Higginson I. Measuring quality of life: )54.8 (Are quality of life)]TJ
1.675 -1.25 Td
(measures patient-centred? BMJ 2001;322:1357-60.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (Kwoh K, Feinstein )54.8 (A, Gif)17.7 (ford R, et al. Physician-patient agreement)]TJ
1.675 -1.25 Td
[(on patients\325)-201.1 (priorities for important treatment outcomes [abstract].)]TJ
T*
(Arthritis Rheum 1987;30 Suppl:S101.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (Daltroy L, Eaton H, Hashimoto H, Liang MH. Rheumatoid arthritis)]TJ
1.675 -1.25 Td
[(patients\325)-201.1 (expectations for treatment outcomes [abstract]. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1995;38 Suppl:S310.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(10.)-875.1 (W)79.9 (oolhead GM, Carr )54.8 (AJ, )17.7 (W)39.9 (ilkinson M, Bannister GC, )54.8 (Ackroyd CE.)]TJ
2.175 -1.25 Td
(Expectations of treatment and outcome in patients awaiting joint)Tj
T*
[(replacement sur)17.7 (gery and general orthopaedic outpatients [abstract].)]TJ
T*
(Arthritis Rheum 1996;39 Suppl:S174.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Mitchell H, Stowers K, Hughes RA, Carr )54.8 (AJ. Patients\325)]TJ
2.1381 -1.25 Td
(self-assessment of disease activity and severity in rheumatoid)Tj
T*
[(arthritis [abstract]. )54.8 (Arthritis Rheum 1999;42 Suppl:S274.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (Carr )54.8 (AJ, Hughes RA, Stowers K. )17.7 (What influences placebo response)]TJ
2.175 -1.25 Td
[(to a complementary therapy)64.8 (, glucosamine sulphate? [abstract].)]TJ
0 Tc T*
(Rheumatology 2000;36:S238.)Tj
ET
0 0 0 0 scn
420 777 137 -27 re
f*
408 770 150 -25 re
f*
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/T1_2 1 Tf
-0.00011 Tc 8 0 0 8 54.5 35.9844 Tm
[(Carr)110.8 (, et al: Rheumatology outcomes)]TJ
0 Tc 0 Tw 61.4375 -0.0313 Td
(883)Tj
ET
0 0 0 0 scn
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
39 0 obj
<>
endobj
40 0 obj
<>
endobj
28 0 obj
<>
endobj
69 0 obj
<>
endobj
83 0 obj
<>
endobj
29 0 obj
<>
endobj
64 0 obj
<>stream
H{PSwro.6F!^WQvUPtyV)Qb !!!e">j->uݱNut{nݍؙuf99988>wƀ!X12:Qڿ87&;N{w'9Bҟ?i
?X>&sT.tECSZYZ.OPsbz/_xkt.gWbVB)*
{ce$